Hepatocellular carcinoma in Italian patients with cirrhosis

Massimo Colombo, Roberto De Franchis, Ersilio Del Ninno, Angelo Sangiovanni, Cristina De Fazio, Maurizio Tommasini, M. Francesca Donato, Anna Piva, Valerio Di Carlo, Nicola Dioguardi

Research output: Contribution to journalArticle

760 Citations (Scopus)

Abstract

Background and Methods. Patients with cirrhosis of the liver are recognized as being at risk for hepatocellular carcinoma. The magnitude of the risk, the natural history of this disease, and the possibilities for detecting potentially curable tumors in patients in the Western world are unknown. To address these questions, we examined 447 Italian patients with well-compensated cirrhosis (which was of viral origin in 62 percent of them) from 1985 through 1990, performing serum alpha-fetoprolein assays and real-time ultrasonography every 3 to 12 months. Results. Hepatocellular carcinoma was found in 30 patients (7 percent) at base line and in another 29 patients (7 percent of 417 patients free of tumor at base line) during follow-up periods averaging 33 months (range, 1 to 48). The cumulative hazard of the development of hepatocellular carcinoma during follow-up was higher among patients with persistently elevated serum alpha-fetoprotein levels (12 with tumors among 42 with such levels) than among those with fluctuating levels (11 among 82) or those with consistently normal levels (6 among 255). Only 17 patients had potentially operable tumors. The proportion of potentially operable tumors among those detected during follow-up was significantly lower than the proportion at enrollment (4 of 29 vs. 13 of 30, P = 0.027). The survival at one year of the 12 patients who underwent surgery was 67 percent, and the tumor-recurrence rate was 60 percent. Outcome was not appreciably different for the five patients who refused surgery. Conclusions. In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent. Our screening program did not appreciably increase the rate of detection of potentially curable tumors.

Original languageEnglish
Pages (from-to)675-680
Number of pages6
JournalNew England Journal of Medicine
Volume325
Issue number10
Publication statusPublished - Sep 5 1991

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Neoplasms
Liver Cirrhosis
Western World
alpha-Fetoproteins
Serum
Ultrasonography
Recurrence
Survival
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatocellular carcinoma in Italian patients with cirrhosis. / Colombo, Massimo; De Franchis, Roberto; Del Ninno, Ersilio; Sangiovanni, Angelo; De Fazio, Cristina; Tommasini, Maurizio; Donato, M. Francesca; Piva, Anna; Di Carlo, Valerio; Dioguardi, Nicola.

In: New England Journal of Medicine, Vol. 325, No. 10, 05.09.1991, p. 675-680.

Research output: Contribution to journalArticle

Colombo, M, De Franchis, R, Del Ninno, E, Sangiovanni, A, De Fazio, C, Tommasini, M, Donato, MF, Piva, A, Di Carlo, V & Dioguardi, N 1991, 'Hepatocellular carcinoma in Italian patients with cirrhosis', New England Journal of Medicine, vol. 325, no. 10, pp. 675-680.
Colombo, Massimo ; De Franchis, Roberto ; Del Ninno, Ersilio ; Sangiovanni, Angelo ; De Fazio, Cristina ; Tommasini, Maurizio ; Donato, M. Francesca ; Piva, Anna ; Di Carlo, Valerio ; Dioguardi, Nicola. / Hepatocellular carcinoma in Italian patients with cirrhosis. In: New England Journal of Medicine. 1991 ; Vol. 325, No. 10. pp. 675-680.
@article{936b9aecbaae45e49b026b2ab224d38f,
title = "Hepatocellular carcinoma in Italian patients with cirrhosis",
abstract = "Background and Methods. Patients with cirrhosis of the liver are recognized as being at risk for hepatocellular carcinoma. The magnitude of the risk, the natural history of this disease, and the possibilities for detecting potentially curable tumors in patients in the Western world are unknown. To address these questions, we examined 447 Italian patients with well-compensated cirrhosis (which was of viral origin in 62 percent of them) from 1985 through 1990, performing serum alpha-fetoprolein assays and real-time ultrasonography every 3 to 12 months. Results. Hepatocellular carcinoma was found in 30 patients (7 percent) at base line and in another 29 patients (7 percent of 417 patients free of tumor at base line) during follow-up periods averaging 33 months (range, 1 to 48). The cumulative hazard of the development of hepatocellular carcinoma during follow-up was higher among patients with persistently elevated serum alpha-fetoprotein levels (12 with tumors among 42 with such levels) than among those with fluctuating levels (11 among 82) or those with consistently normal levels (6 among 255). Only 17 patients had potentially operable tumors. The proportion of potentially operable tumors among those detected during follow-up was significantly lower than the proportion at enrollment (4 of 29 vs. 13 of 30, P = 0.027). The survival at one year of the 12 patients who underwent surgery was 67 percent, and the tumor-recurrence rate was 60 percent. Outcome was not appreciably different for the five patients who refused surgery. Conclusions. In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent. Our screening program did not appreciably increase the rate of detection of potentially curable tumors.",
author = "Massimo Colombo and {De Franchis}, Roberto and {Del Ninno}, Ersilio and Angelo Sangiovanni and {De Fazio}, Cristina and Maurizio Tommasini and Donato, {M. Francesca} and Anna Piva and {Di Carlo}, Valerio and Nicola Dioguardi",
year = "1991",
month = "9",
day = "5",
language = "English",
volume = "325",
pages = "675--680",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - Hepatocellular carcinoma in Italian patients with cirrhosis

AU - Colombo, Massimo

AU - De Franchis, Roberto

AU - Del Ninno, Ersilio

AU - Sangiovanni, Angelo

AU - De Fazio, Cristina

AU - Tommasini, Maurizio

AU - Donato, M. Francesca

AU - Piva, Anna

AU - Di Carlo, Valerio

AU - Dioguardi, Nicola

PY - 1991/9/5

Y1 - 1991/9/5

N2 - Background and Methods. Patients with cirrhosis of the liver are recognized as being at risk for hepatocellular carcinoma. The magnitude of the risk, the natural history of this disease, and the possibilities for detecting potentially curable tumors in patients in the Western world are unknown. To address these questions, we examined 447 Italian patients with well-compensated cirrhosis (which was of viral origin in 62 percent of them) from 1985 through 1990, performing serum alpha-fetoprolein assays and real-time ultrasonography every 3 to 12 months. Results. Hepatocellular carcinoma was found in 30 patients (7 percent) at base line and in another 29 patients (7 percent of 417 patients free of tumor at base line) during follow-up periods averaging 33 months (range, 1 to 48). The cumulative hazard of the development of hepatocellular carcinoma during follow-up was higher among patients with persistently elevated serum alpha-fetoprotein levels (12 with tumors among 42 with such levels) than among those with fluctuating levels (11 among 82) or those with consistently normal levels (6 among 255). Only 17 patients had potentially operable tumors. The proportion of potentially operable tumors among those detected during follow-up was significantly lower than the proportion at enrollment (4 of 29 vs. 13 of 30, P = 0.027). The survival at one year of the 12 patients who underwent surgery was 67 percent, and the tumor-recurrence rate was 60 percent. Outcome was not appreciably different for the five patients who refused surgery. Conclusions. In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent. Our screening program did not appreciably increase the rate of detection of potentially curable tumors.

AB - Background and Methods. Patients with cirrhosis of the liver are recognized as being at risk for hepatocellular carcinoma. The magnitude of the risk, the natural history of this disease, and the possibilities for detecting potentially curable tumors in patients in the Western world are unknown. To address these questions, we examined 447 Italian patients with well-compensated cirrhosis (which was of viral origin in 62 percent of them) from 1985 through 1990, performing serum alpha-fetoprolein assays and real-time ultrasonography every 3 to 12 months. Results. Hepatocellular carcinoma was found in 30 patients (7 percent) at base line and in another 29 patients (7 percent of 417 patients free of tumor at base line) during follow-up periods averaging 33 months (range, 1 to 48). The cumulative hazard of the development of hepatocellular carcinoma during follow-up was higher among patients with persistently elevated serum alpha-fetoprotein levels (12 with tumors among 42 with such levels) than among those with fluctuating levels (11 among 82) or those with consistently normal levels (6 among 255). Only 17 patients had potentially operable tumors. The proportion of potentially operable tumors among those detected during follow-up was significantly lower than the proportion at enrollment (4 of 29 vs. 13 of 30, P = 0.027). The survival at one year of the 12 patients who underwent surgery was 67 percent, and the tumor-recurrence rate was 60 percent. Outcome was not appreciably different for the five patients who refused surgery. Conclusions. In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent. Our screening program did not appreciably increase the rate of detection of potentially curable tumors.

UR - http://www.scopus.com/inward/record.url?scp=0025887360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025887360&partnerID=8YFLogxK

M3 - Article

C2 - 1651452

AN - SCOPUS:0025887360

VL - 325

SP - 675

EP - 680

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -